Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) addressed tuberculosis testing adoption at The Union World Conference on Lung Health on Nov 20, 2025 in Copenhagen.
The company highlighted its upcoming Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test Kit and a proprietary sample-preparation instrument for point-of-care testing on the Co-Dx PCR Pro platform. Co-Dx said it is planning clinical performance testing to begin soon and anticipates potential introduction to India and South Africa, noting a target of decentralized PCR access to nearly 30,000 primary health centers in India. Management also said it is exploring a possible strategic transaction, which may include a merger with a SPAC, for its Indian joint venture CoSara Diagnostics Pvt. Ltd. The Co-Dx PCR platform is under regulatory review and not available for sale.
Positive
- Clinical performance testing planned to begin soon
- Targets decentralized PCR for nearly 30,000 Indian primary health centers
- Developed proprietary sample-preparation instrument for point-of-care workflow
Negative
- Co-Dx PCR platform is under regulatory review and not available for sale
- Strategic transaction for CoSara is exploratory with an uncertain outcome
News Market Reaction
On the day this news was published, CODX declined 5.84%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.9% during that session. Argus tracked a trough of -3.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $22M at that time.
Data tracked by StockTitan Argus on the day of publication.
For over 100 years, The Union World Conference on Lung Health has come together to present the latest scientific research in all aspects of lung health. This year's event falls shortly after the Company announced the development of a proprietary sample preparation instrument for point-of-care testing, designed to offer a streamlined and simplified workflow for the upcoming point-of-care Co-Dx™ PCR Mycobacterium Tuberculosis (MTB) Test Kit on the Co-Dx PCR Pro* instrument.
The Company is planning for clinical performance testing of this new test to begin soon, and anticipates that the potential introduction to the Indian and South African markets will address testing needs for the deadliest infectious disease in the world, which is nonetheless highly treatable and curable if diagnosed early. Co-Dx believes that making decentralized PCR available to the nearly 30,000 primary health centers across
Co-Dx management also recently announced that it is exploring the possibility of a strategic transaction (which may include a merger with a SPAC) for CoSara Diagnostics Pvt. Ltd., its Indian joint venture, which the Company believes would help CoSara fully realize its founding mission of increasing the availability of high-quality molecular diagnostic products at accessible prices.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Forward-looking statements include statements made with respect to our Co-Dx PCR platform and MTB test, including statements about potential or future clinical evaluations, regulatory submissions, product performance, market opportunities, or commercialization efforts related to the Co-Dx PCR platform and associated tests. Forward-looking statements also include statements regarding strategic transaction evaluations related to CoSara Diagnostics. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2025, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-delivers-address-about-tuberculosis-test-adoption-and-implementation-at-the-union-world-conference-on-lung-health-302621453.html
SOURCE Co-Diagnostics
FAQ
What did Co-Diagnostics (CODX) announce at The Union World Conference on Lung Health on Nov 20, 2025?
When will Co-Diagnostics begin clinical performance testing for the Co-Dx PCR MTB test (CODX)?
Will the Co-Dx PCR MTB test be available in India and South Africa (CODX)?
Is the Co-Dx PCR platform (CODX) cleared for sale by regulators?
What is the status of the CoSara Diagnostics transaction mentioned by Co-Diagnostics (CODX)?
